AI Engines For more Details: Perplexity Kagi Labs You
Nausea and Vomiting: Droperidol is commonly used to prevent and treat nausea and vomiting, particularly in surgical and postoperative settings. It is often administered intravenously before surgery or anesthesia to reduce the risk of postoperative nausea and vomiting (PONV).
Sedation: Droperidol has sedative properties and may be used to induce sedation and calmness in patients undergoing certain medical procedures or experiencing acute agitation or anxiety.
Anesthesia: In anesthesia practice, droperidol can be used as an adjunctive medication to enhance the effects of other anesthetics or to manage intraoperative nausea and vomiting.
Psychotic Disorders: Droperidol belongs to a class of medications known as antipsychotics. It may be used in the management of psychotic disorders such as schizophrenia or acute psychotic episodes characterized by hallucinations, delusions, or disorganized thinking.
Agitation and Behavioral Disturbances: Droperidol may be prescribed to control agitation and behavioral disturbances associated with psychiatric conditions or acute medical illness.
Chemotherapy-induced Nausea and Vomiting: It can be used to prevent and alleviate nausea and vomiting induced by chemotherapy treatments for cancer.
Migraine: Droperidol may be used in the emergency department to treat severe migraines that have not responded to other medications. It can help relieve nausea and vomiting associated with migraines and provide sedation during treatment.
Postoperative Pain: Droperidol has been studied for its potential role in enhancing pain relief and reducing opioid requirements in the postoperative period.
Acute Agitation in Emergency Settings: In emergency medicine, droperidol may be used to manage acute agitation and violent behavior in patients with conditions such as drug intoxication, delirium, or psychosis.
Hiccups: Droperidol has been used off-label to treat persistent or intractable hiccups that have not responded to other treatments.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.8 | 0.6 | 3.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.5 | 1.7 | 0.47 |
| Allergies | 3.6 | 2.7 | 0.33 |
| Allergy to milk products | 2.1 | 1.6 | 0.31 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 4.9 | 5.3 | -0.08 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.6 | 1 | 1.6 |
| Ankylosing spondylitis | 3.9 | 1 | 2.9 |
| Anorexia Nervosa | 1.2 | 2 | -0.67 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 3.2 | 2.8 | 0.14 |
| Atherosclerosis | 1.7 | 2 | -0.18 |
| Atrial fibrillation | 2.3 | 2.6 | -0.13 |
| Autism | 8.1 | 7.5 | 0.08 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.1 | 2.1 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.9 | 0.9 | 0 |
| Carcinoma | 3.8 | 1.6 | 1.37 |
| Celiac Disease | 3 | 2.4 | 0.25 |
| Cerebral Palsy | 1.8 | 0.8 | 1.25 |
| Chronic Fatigue Syndrome | 3.8 | 3.4 | 0.12 |
| Chronic Kidney Disease | 2.9 | 2.1 | 0.38 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.7 | 0.12 |
| Chronic Urticaria (Hives) | 1.8 | 1.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.8 | 1.13 |
| Cognitive Function | 1.6 | 1.6 | 0 |
| Colorectal Cancer | 6.8 | 2.6 | 1.62 |
| Constipation | 1.5 | 0.5 | 2 |
| Coronary artery disease | 2.3 | 2 | 0.15 |
| COVID-19 | 5.7 | 7 | -0.23 |
| Crohn's Disease | 8 | 4.1 | 0.95 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1 | 1.2 | -0.2 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.3 | 1.1 | 1.09 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 8.8 | 7.4 | 0.19 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.1 | 1 | 1.1 |
| Endometriosis | 2.6 | 1.8 | 0.44 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.4 | 2.1 | 0.62 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 1.8 | 1.7 | 0.06 |
| Functional constipation / chronic idiopathic constipation | 4.5 | 2.9 | 0.55 |
| gallstone disease (gsd) | 2.5 | 1.6 | 0.56 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.8 | 0.3 | 5 |
| Generalized anxiety disorder | 3.4 | 1.8 | 0.89 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 1 | 0.3 |
| Graves' disease | 1.6 | 2.3 | -0.44 |
| Gulf War Syndrome | 0.8 | 1.5 | -0.88 |
| Halitosis | 1.6 | 0.3 | 4.33 |
| Hashimoto's thyroiditis | 2.3 | 1.4 | 0.64 |
| Heart Failure | 3.4 | 1.5 | 1.27 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 0.9 | 0.6 | 0.5 |
| hyperglycemia | 2 | 2.1 | -0.05 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.3 | 3.3 | 0 |
| Hypothyroidism | 0.5 | 0.9 | -0.8 |
| Hypoxia | 3.1 | 0.3 | 9.33 |
| IgA nephropathy (IgAN) | 1.6 | 2.9 | -0.81 |
| Inflammatory Bowel Disease | 6.8 | 7.1 | -0.04 |
| Insomnia | 1.2 | 2.8 | -1.33 |
| Intelligence | 1.5 | 0.5 | 2 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 5.7 | 5 | 0.14 |
| ischemic stroke | 2 | 1.7 | 0.18 |
| Liver Cirrhosis | 6.5 | 4.9 | 0.33 |
| Long COVID | 6.1 | 4 | 0.52 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.2 | 0.6 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.3 | 0.6 | 1.17 |
| ME/CFS with IBS | 1 | 0.7 | 0.43 |
| ME/CFS without IBS | 1.4 | 1.1 | 0.27 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.4 | 1 | -1.5 |
| Metabolic Syndrome | 6.6 | 6.1 | 0.08 |
| Mood Disorders | 9 | 6 | 0.5 |
| multiple chemical sensitivity [MCS] | 1.2 | 1.2 | |
| Multiple Sclerosis | 5.4 | 4 | 0.35 |
| Multiple system atrophy (MSA) | 1.7 | 0.3 | 4.67 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 2.3 | -6.67 |
| Neuropathy (all types) | 1.1 | 1.7 | -0.55 |
| neuropsychiatric disorders (PANDAS, PANS) | 1 | 1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.7 | 3 | 0.23 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 8.2 | 6.5 | 0.26 |
| obsessive-compulsive disorder | 3.4 | 3.3 | 0.03 |
| Osteoarthritis | 2.1 | 1.4 | 0.5 |
| Osteoporosis | 2.2 | 1.2 | 0.83 |
| pancreatic cancer | 1 | 0.3 | 2.33 |
| Parkinson's Disease | 6.6 | 4.9 | 0.35 |
| Polycystic ovary syndrome | 4.9 | 2.7 | 0.81 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.6 | 1.4 | -1.33 |
| Primary sclerosing cholangitis | 2.3 | 1.9 | 0.21 |
| Psoriasis | 2.3 | 3.3 | -0.43 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.7 | 3 | 0.9 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 5.1 | 2.8 | 0.82 |
| scoliosis | 0.7 | 0.3 | 1.33 |
| Sjögren syndrome | 2.7 | 1.7 | 0.59 |
| Sleep Apnea | 0.9 | 1.4 | -0.56 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 2.1 | |
| Stress / posttraumatic stress disorder | 2.9 | 2.9 | 0 |
| Systemic Lupus Erythematosus | 4.1 | 1.2 | 2.42 |
| Tic Disorder | 1.2 | 1.1 | 0.09 |
| Tourette syndrome | 0.8 | 0.3 | 1.67 |
| Type 1 Diabetes | 3.6 | 2.3 | 0.57 |
| Type 2 Diabetes | 7.8 | 5.5 | 0.42 |
| Ulcerative colitis | 4.4 | 5.7 | -0.3 |
| Unhealthy Ageing | 4.1 | 2.5 | 0.64 |
| Vitiligo | 1.4 | 1.6 | -0.14 |
